

## General

### Title

Cutaneous melanoma: proportion of patients with stage III and IV cutaneous melanoma who undergo CT or positron emission tomography (PET) CT prior to completion lymphadenectomy.

### Source(s)

NHS Scotland, Scottish Cancer Taskforce. Cutaneous melanoma clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 Feb. 32 p. [27 references]

## Measure Domain

### Primary Measure Domain

Clinical Quality Measures: Process

### Secondary Measure Domain

Does not apply to this measure

## Brief Abstract

### Description

This measure is used to assess the proportion of patients with stage III and IV cutaneous melanoma who undergo computed tomography (CT) or positron emission tomography (PET) CT prior to completion lymphadenectomy.

Note from the National Quality Measures Clearinghouse: This measure is part of the Cancer Quality Performance Indicators (QPIs) collection. For more information, including a complete list of QPI measure sets, please visit the [Healthcare Improvement Scotland Web site](#).

### Rationale

Evidence found that patients should be imaged by computed tomography (CT) prior to surgery, with specialist skin cancer multidisciplinary team review (Marsden et al., 2010).

Guidelines report that patients with high grade cutaneous melanoma should undergo imaging of the head, chest, abdomen and pelvis to exclude metastases (Marsden et al., 2010). It has been reported that low

grade cutaneous melanoma does not benefit from imaging due to the high incident rate of false positives (Marsden et al., 2010; Scottish Intercollegiate Guidelines Network [SIGN], 2003). To ensure alignment with current clinical practice stage has been utilised to stratify patients for inclusion within this Cancer Quality Performance Indicator (QPI) over grading.

## Evidence for Rationale

Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, MacKie R, Nathan P, Peach H, Powell B, Walker C, British Association of Dermatologists Clinical Standards Unit. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol. 2010 Aug;163(2):238-56. [143 references] [PubMed](#)

NHS Scotland, Scottish Cancer Taskforce. Cutaneous melanoma clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 Feb. 32 p. [27 references]

Scottish Intercollegiate Guidelines Network (SIGN). Cutaneous melanoma. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2003 Jul. 50 p. (SIGN publication; no. 72). [277 references]

## Primary Health Components

Stage III and IV cutaneous melanoma; lymphadenectomy; computed tomography (CT); positron emission tomography (PET)

## Denominator Description

All patients with stage III and IV cutaneous melanoma undergoing completion lymphadenectomy

## Numerator Description

Number of patients with stage III and IV cutaneous melanoma undergoing completion lymphadenectomy who undergo computed tomography (CT) or positron emission tomography (PET) CT prior to completion lymphadenectomy

## Evidence Supporting the Measure

### Type of Evidence Supporting the Criterion of Quality for the Measure

A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence

A formal consensus procedure, involving experts in relevant clinical, methodological, public health and organizational sciences

### Additional Information Supporting Need for the Measure

Unspecified

## Extent of Measure Testing

The collection of data is piloted on a small number of patient records using a paper data collection form produced by the Information Services Division (ISD). The aim is to identify any anomalies or difficulties with data collection prior to full implementation. At least one NHS board in each Regional Cancer Network participates in the pilot.

## Evidence for Extent of Measure Testing

NHS Scotland. National cancer quality performance indicators: overview of development process. Edinburgh (Scotland): NHS Scotland; 2012 Dec. 7 p.

## State of Use of the Measure

### State of Use

Current routine use

### Current Use

not defined yet

## Application of the Measure in its Current Use

### Measurement Setting

Ambulatory Procedure/Imaging Center

Hospital Inpatient

Hospital Outpatient

### Professionals Involved in Delivery of Health Services

not defined yet

### Least Aggregated Level of Services Delivery Addressed

Single Health Care Delivery or Public Health Organizations

### Statement of Acceptable Minimum Sample Size

Unspecified

### Target Population Age

Unspecified

## Target Population Gender

Either male or female

# National Strategy for Quality Improvement in Health Care

## National Quality Strategy Aim

Better Care

## National Quality Strategy Priority

Prevention and Treatment of Leading Causes of Mortality

# Institute of Medicine (IOM) National Health Care Quality Report Categories

## IOM Care Need

Living with Illness

## IOM Domain

Effectiveness

# Data Collection for the Measure

## Case Finding Period

Unspecified

## Denominator Sampling Frame

Patients associated with provider

## Denominator (Index) Event or Characteristic

Clinical Condition

Therapeutic Intervention

## Denominator Time Window

not defined yet

## Denominator Inclusions/Exclusions

### Inclusions

All patients with stage III and IV cutaneous melanoma undergoing completion lymphadenectomy

### Exclusions

None

## Exclusions/Exceptions

not defined yet

## Numerator Inclusions/Exclusions

### Inclusions

Number of patients with stage III and IV cutaneous melanoma undergoing completion lymphadenectomy who undergo computed tomography (CT) or positron emission tomography (PET) CT prior to completion lymphadenectomy

### Exclusions

None

## Numerator Search Strategy

Fixed time period or point in time

## Data Source

Electronic health/medical record

Paper medical record

## Type of Health State

Does not apply to this measure

## Instruments Used and/or Associated with the Measure

Unspecified

## Computation of the Measure

## Measure Specifies Disaggregation

Does not apply to this measure

## Scoring

Rate/Proportion

## Interpretation of Score

Desired value is a higher score

## Allowance for Patient or Population Factors

not defined yet

## Standard of Comparison

not defined yet

## Prescriptive Standard

Target: 95%

The tolerance within this target accounts for situations where patients are not fit enough to undergo investigation and for factors of patient choice

## Evidence for Prescriptive Standard

NHS Scotland, Scottish Cancer Taskforce. Cutaneous melanoma clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 Feb. 32 p. [27 references]

## Identifying Information

### Original Title

QPI 9 – imaging for patients with advanced melanoma.

### Measure Collection Name

Cancer Quality Performance Indicators (QPIs)

### Measure Set Name

Cutaneous Melanoma

### Submitter

NHS Scotland - National Government Agency [Non-U.S.]

Scottish Cancer Taskforce - National Government Agency [Non-U.S.]

### Developer

NHS Scotland - National Government Agency [Non-U.S.]

## Funding Source(s)

Scottish Government

## Composition of the Group that Developed the Measure

Cutaneous Melanoma QPI Development Group

## Financial Disclosures/Other Potential Conflicts of Interest

Unspecified

## Adaptation

This measure was not adapted from another source.

## Date of Most Current Version in NQMC

2016 Feb

## Measure Maintenance

The Cancer Quality Performance Indicators (QPIs) will be kept under regular review and be responsive to changes in clinical practice and emerging evidence.

## Date of Next Anticipated Revision

2017 Dec

## Measure Status

This is the current release of the measure.

## Measure Availability

Source document available from the [Healthcare Improvement Scotland Web site](#) .

For more information, contact the Healthcare Improvement Scotland at Gyle Square, 1 South Gyle Crescent, Edinburgh, Scotland EH12 9EB; Phone: 0131 623 4300; E-mail: [comments.his@nhs.net](mailto:comments.his@nhs.net); Web site: [www.healthcareimprovementscotland.org/](http://www.healthcareimprovementscotland.org/) .

## Companion Documents

The following is available:

NHS Scotland. National cancer quality performance indicators: overview of development process. Edinburgh (Scotland): NHS Scotland; 2012 Dec. 7 p. This document is available from the [Healthcare](#)

## NQMC Status

This NQMC summary was completed by ECRI Institute on June 16, 2017.

## Copyright Statement

No copyright restrictions apply.

## Production

## Source(s)

NHS Scotland, Scottish Cancer Taskforce. Cutaneous melanoma clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 Feb. 32 p. [27 references]

## Disclaimer

### NQMC Disclaimer

The National Quality Measures Clearinghouse<sup>®</sup> (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the [NQMC Inclusion Criteria](#).

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.